Azathioprine (AZA), a common immunosuppressant, has been reported to cause bone marrow suppression in infants when used during pregnancy and breast-feeding.
associated with decreased enzymatic activity. Moreover, these polymorphisms are associated with increased myelosuppression risk, 5 as decreased TPMT activity leads to elevated 6TGN levels. 6 Severe renal dysfunction has been reported to raise 6TGN levels by 8-to >10-fold. 7 Here we report a case in which an infant with pancytopenia was born to a mother who had used AZA during pregnancy and breast-feeding. Maternal and neonatal blood 6TGN levels were obtained with written informed consent from the mother.
Case Report
A boy was born to a 31-year-old primiparous woman with a history of renal transplantation at age 22 due to Goodpasture's syndrome. She had been well maintained on AZA, 
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Abstract
An infant with pancytopenia was born to a mother who used the common immunosuppressant azathioprine (AZA). Maternal and neonatal blood levels of 6-thioguanine nucleotides (6TGN; metabolite of AZA) were 1890 and 1480 pmol/8 Â 10 8 red blood cells, respectively. Maternal 6TGN levels could be useful in predicting neonatal pancytopenia.
requiring oxygen supplementation at day 1 and nasal directional positive airway pressure at day 3. Leukocytopenia, lymphocytopenia, and macrocytic hyperchromatic anemia were noted at birth (►Table 1). There was no ABO incompatibility or fetomaternal transfusion. Maternal and neonatal blood levels of 6TGN were 1890 pmol/8 Â 10 8 red blood cells (RBC) at day 2 and 1480 pmol/8 Â 10 8 RBC at day 3, respectively. Neonatal CsA level was <30 ng/mL at day 3. Blood test results were negative for cytomegalovirus infection. The boy later developed thrombocytopenia (►Fig. 2). Breast-feeding was started at day 0, and fortified milk was added at day 6; breast-feeding was stopped at day 16 due to maternal steroid pulse therapy. Neonatal 6TGN levels gradually decreased, which was well approximated to the exponential function: y ¼ 1659e À0.074x ,
The baby gained weight properly and was discharged at day 32. At 4 months of age (corrected: 3 months old), physical and mental development were normal. The TPMT genotype of the mother was not determined.
Discussion
Maternal AZA dose at the time of delivery was 75 mg/d (1.5 mg/kg/d), which is a normal dose used clinically. 8 However, maternal 6TGN levels at day 2 (1890 pmol/8 Â 10 8 RBC)
were extremely high, which could have been attributed to TPMT polymorphism and/or maternal renal dysfunction.
5-7,9
Despite the high 6TGN levels, the mother did not present with leukocytopenia or thrombocytopenia. Hanai et al reported that leukocytopenia was observed when 6TGN levels exceeded 320 pmol/8 Â 10 8 RBC, with an incidence of approximately 20%. 6 And Lennard et al showed that the patient had leukocytopenia when 6TGN level went over 300 pmol/ 8 Â 10 8 RBC. 10 Thus, less than 300 pmol/8 Â 10 8 RBC would not be high. We did not check TPMT polymorphism or TPMT activity. There was an inverse relationship between 6TGN levels in RBC and TPMT enzyme activity in the patients who had 6 mercaptopurine, 6 which was metabolized to 6TGN. The range of 6TGN level in the blood was from 100 to 700 pmol/ 8 Â 10 8 RBC. Thus, we could not easily estimate the 6TGN level. At day 3, when the infant did not have sufficient breast milk, neonatal 6TGN levels remained high, suggesting that these high levels were due to exposure through the placenta. As neonatal 6TGN levels declined, pancytopenia gradually improved.
In conclusion, there was no correlation between maternal AZA dose and maternal blood 6TGN levels. Furthermore, no distinct side effects were observed in the mother despite her high 6TGN levels. Taken together, our findings suggest that maternal blood 6TGN levels could be used to predict fetal pancytopenia. Fig. 3 The trend of neonatal 6-thioguanine nucleotides (6TGN) levels is shown. It was approximated to the exponential function: y ¼ 1659e À0.074x , R 2 ¼ 0.972. RBC, red blood cells.
